The Cost of Thromboembolic Events in Hospitalized Patients with Breast or Prostate Cancer in France

Conclusion The burden of VTE in cancer patients is important; costs should be reduced by decreasing the occurrence of thrombotic recurrences. In this respect, better prevention and follow-up measures may reduce recurrence and VTE costs.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research